Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2006

01-02-2006 | Original Article

Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer

Authors: Yuka Yamamoto, Yoshihiro Nishiyama, Toshihide Monden, Yasuhiro Sasakawa, Motoomi Ohkawa, Masashi Gotoh, Kotaro Kameyama, Reiji Haba

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2006

Login to get access

Abstract

Purpose

The objective of this study was to evaluate the ability of FDG-PET to predict the response of primary tumour and nodal disease to preoperative induction chemoradiotherapy in patients with non-small cell lung cancer (NSCLC).

Methods

FDG-PET studies were performed before and after completion of chemoradiotherapy prior to surgery in 26 patients with NSCLC. FDG-PET imaging was performed at 1 h (early) and 2 h (delayed) after injection. Semi-quantitative analysis was performed using the standardised uptake value (SUV) at the primary tumour. Percent change was calculated according to the following equation: \({\left( {{\text{SUV}}_{{{\text{after}}}} - {\text{SUV}}_{{{\text{before}}}} } \right)} \times {100} \mathord{\left/ {\vphantom {{100} {{\text{SUV}}_{{{\text{before}}}} }}} \right. \kern-\nulldelimiterspace} {{\text{SUV}}_{{{\text{before}}}} }\). Based on histopathological analysis of the specimens obtained at surgery, patients were classified as pathological responders or pathological non-responders. The clinical nodal stage on the post-chemoradiotherapy PET scan was visually determined and compared with the final pathological stage.

Results

Eighteen patients were found to be pathological responders and eight to be pathological non-responders. SUVafter values from both early and delayed images in pathological responders were significantly lower than those in pathological non-responders. The percent change values from early and delayed images in the pathological responders were significantly higher than those in the pathological non-responders. The post-chemoradiotherapy PET scan accurately predicted nodal stage in 22 of 26 patients.

Conclusion

FDG-PET may have the potential to predict response to induction chemoradiotherapy in patients with NSCLC.
Literature
1.
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23–47PubMed
2.
Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365–73PubMed
3.
Rusch V, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup trial 0160). J Thorac Cardiovasc Surg 2001;121:472–83CrossRefPubMed
4.
Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003;21:1285–92CrossRefPubMed
5.
Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic mapping. Ann Thorac Surg 1995;60:1573–82CrossRefPubMed
6.
Gambhir SS, Hoh CG, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in staging and management of non-small cell lung cancer. J Nucl Med 1996;37:428–36
7.
Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655–60PubMed
8.
Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416–21CrossRefPubMed
9.
Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384–6PubMed
10.
Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412–7PubMed
11.
Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6PubMed
12.
Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696–703CrossRefPubMed
13.
Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–5PubMed
14.
Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2002;44:540–8
15.
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–23PubMed
16.
Lee K, Shim YM, Han J, Kim J, Ahn YC, Park K, et al. Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation. J Comput Assist Tomogr 2000;24:35–40CrossRefPubMed
17.
Pauwels EK, McCready VR, Stoot JH, van Deurzen DF. The mechanism of accumulation of tumor-localizing pharamaceuticals. Eur J Nucl Med 1998;25:277–305CrossRefPubMed
18.
Oya N, Nagata Y, Tamaki N, Takagi T, Murata R, Magata Y, et al. FDG-PET evaluation of therapeutic effects on VX2 liver tumor. J Nucl Med 1996;37:296–302PubMed
19.
Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study—The Leuven Lung Cancer Group. Ann Oncol 1998;9:1193–8CrossRefPubMed
20.
Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259–64CrossRefPubMed
21.
Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179–87CrossRefPubMed
22.
Fischman AJ, Thornton AF, Frosch MP, Swearinger B, Gonzalez RG, Alpert NM. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. J Nucl Med 1997;38:1027–9PubMed
23.
Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, l-methionine and thymidine. J Nucl Med 1997;38:280–7PubMed
24.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of F-18-fluoro-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography. J Nucl Med 1992;33:1972–80PubMed
25.
Haberkorn U, Strauss LG, Dimitrakopoupou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485–90PubMed
26.
Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521–7CrossRefPubMed
Metadata
Title
Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
Authors
Yuka Yamamoto
Yoshihiro Nishiyama
Toshihide Monden
Yasuhiro Sasakawa
Motoomi Ohkawa
Masashi Gotoh
Kotaro Kameyama
Reiji Haba
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-1878-9

Other articles of this Issue 2/2006

European Journal of Nuclear Medicine and Molecular Imaging 2/2006 Go to the issue

Letter to the Editor

The number of subsets required for OSEM reconstruction in nuclear cardiology

Editorial

The European Board of Nuclear Medicine Fellowship Examination

Original Article

The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study

Original Article

Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated SPECT with 99mTc-tetrofosmin: a multicentre study involving 106 hospitals

Original Article

Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users

Original Article

Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment